Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Coherus BioSciences Q3 Adj. EPS $(0.33) Misses $(0.29) Estimate, Sales $11.571M Miss $13.413M Estimate

Author: Benzinga Newsdesk | November 06, 2025 04:22pm
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 3200 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $11.571 million which missed the analyst consensus estimate of $13.413 million by 13.73 percent. This is a 91.19 percent increase over sales of $6.052 million the same period last year.

Posted In: CHRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist